Metformin in cancer treatment and prevention

Daniel R. Morales; Andrew D. Morris

doi:10.1146/annurev-med-062613-093128

Metformin in cancer treatment and prevention

Daniel R. Morales (Lead / Corresponding author)
, Andrew D. Morris (Lead / Corresponding author)

Research output: Contribution to journal › Article

435 Citations (Scopus)

Abstract

Patients with diabetes mellitus are at increased risk of cancer development. Metformin is a well-established, effective agent for the management of type 2 diabetes mellitus. Epidemiological studies have identified an association between metformin use and a beneficial effect on cancer prevention and treatment, which has led to increasing interest in the potential use of metformin as an anticancer agent. Basic science has provided a better understanding of the mechanism of action of metformin and the potential for metformin to modulate molecular pathways involved in cancer cell signaling and metabolism. This article outlines the link between metformin and cancer, the potential for metformin in oncology, and limitations of currently available evidence.

Original language	English
Pages (from-to)	17-29
Number of pages	13
Journal	Annual Review of Medicine
Volume	66
Early online date	6 Nov 2014
DOIs	https://doi.org/10.1146/annurev-med-062613-093128
Publication status	Published - Jan 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Diabetes Mellitus, Type 2
Humans
Hypoglycemic Agents
Metformin
Neoplasms
Journal Article
Research Support, Non-U.S. Gov't
Review

Access to Document

10.1146/annurev-med-062613-093128

Cite this

@article{d2fb6a0e7fa649eb82f072a22825b131,

title = "Metformin in cancer treatment and prevention",

abstract = "Patients with diabetes mellitus are at increased risk of cancer development. Metformin is a well-established, effective agent for the management of type 2 diabetes mellitus. Epidemiological studies have identified an association between metformin use and a beneficial effect on cancer prevention and treatment, which has led to increasing interest in the potential use of metformin as an anticancer agent. Basic science has provided a better understanding of the mechanism of action of metformin and the potential for metformin to modulate molecular pathways involved in cancer cell signaling and metabolism. This article outlines the link between metformin and cancer, the potential for metformin in oncology, and limitations of currently available evidence.",

keywords = "Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Journal Article, Research Support, Non-U.S. Gov't, Review",

author = "Morales, \{Daniel R.\} and Morris, \{Andrew D.\}",

year = "2015",

month = jan,

doi = "10.1146/annurev-med-062613-093128",

language = "English",

volume = "66",

pages = "17--29",

journal = "Annual Review of Medicine",

issn = "1545-326X",

publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Metformin in cancer treatment and prevention

AU - Morales, Daniel R.

AU - Morris, Andrew D.

PY - 2015/1

Y1 - 2015/1

N2 - Patients with diabetes mellitus are at increased risk of cancer development. Metformin is a well-established, effective agent for the management of type 2 diabetes mellitus. Epidemiological studies have identified an association between metformin use and a beneficial effect on cancer prevention and treatment, which has led to increasing interest in the potential use of metformin as an anticancer agent. Basic science has provided a better understanding of the mechanism of action of metformin and the potential for metformin to modulate molecular pathways involved in cancer cell signaling and metabolism. This article outlines the link between metformin and cancer, the potential for metformin in oncology, and limitations of currently available evidence.

AB - Patients with diabetes mellitus are at increased risk of cancer development. Metformin is a well-established, effective agent for the management of type 2 diabetes mellitus. Epidemiological studies have identified an association between metformin use and a beneficial effect on cancer prevention and treatment, which has led to increasing interest in the potential use of metformin as an anticancer agent. Basic science has provided a better understanding of the mechanism of action of metformin and the potential for metformin to modulate molecular pathways involved in cancer cell signaling and metabolism. This article outlines the link between metformin and cancer, the potential for metformin in oncology, and limitations of currently available evidence.

KW - Diabetes Mellitus, Type 2

KW - Humans

KW - Hypoglycemic Agents

KW - Metformin

KW - Neoplasms

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

KW - Review

U2 - 10.1146/annurev-med-062613-093128

DO - 10.1146/annurev-med-062613-093128

M3 - Article

C2 - 25386929

SN - 1545-326X

VL - 66

SP - 17

EP - 29

JO - Annual Review of Medicine

JF - Annual Review of Medicine

ER -

Metformin in cancer treatment and prevention

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this